RayKnowChina Research Map
Shortlist0

RecruitingHepatocellular carcinomaEarly phase 1

Registered title, quoted from ClinicalTrials.gov

The Treatment of Bioartificial Liver With hiHep Cells After Extensive Hepatectomy

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Sir Run Run Shaw Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorSir Run Run Shaw Hospital浙江大学医学院附属邵逸夫医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05035108, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 30 years to 80 years; sex: all

    Registered eligibility fields

  2. The platelet count is less than 50,000/μL and cannot be corrected;

    Exclusion criterion 6

  3. HIV, HDV or HCV positive;

    Exclusion criterion 8

  4. Combined pregnancy;

    Exclusion criterion 12

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05035108, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Diagnosed as liver cancer, hepatolithiasis, benign liver tumor, with clear indications for liver resection;
  • Liver function Child A-B;
  • There is no contraindication to surgery for cardiopulmonary function;
  • The expected remaining liver volume/standard liver volume is less than 50%;

Exclusion Criteria:

  • In the late stage of the disease, patients with frequent symptoms such as cerebral edema accompanied by cerebral herniation and clinical evidence indicating intracranial hemorrhage;
  • PaO2/FiO2 is less than 200 and cannot be corrected;
  • Patients with diffuse intravascular coagulation;
  • Those with active bleeding;
  • Uncontrolled infection;
  • The platelet count is less than 50,000/μL and cannot be corrected;
  • There is no blood vessel available for dialysis treatment;
  • HIV, HDV or HCV positive;
  • Drug abuse within 1 year;
  • Those with severe systemic circulatory failure;
  • Those who are highly allergic to the drugs used in the treatment process, such as plasma, heparin, protamine, etc.;
  • Combined pregnancy;
  • Patients with hepatorenal syndrome;
  • Patients with autoimmune liver disease;
  • Patients with non-alcoholic fatty liver and hereditary liver diseases (Wilson syndrome and a-antitrypsin deficiency);
  • Other conditions that the clinician believes cannot tolerate the treatment.

Quoted from ClinicalTrials.gov, NCT05035108, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05035108, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05035108